Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Zentalis has developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.
Zentalis was founded in 2014 and is headquartered in New York, New York, with an office in San Diego, California.
Zentalis’ pipeline candidates that will be developed in China by Zentera include its oral SERD (ZN-c5), WEE1 inhibitor (ZN-c3), and BCL-2 inhibitor (ZN-d5), which address unmet medical needs in large patient populations in both solid and liquid tumors. Additional Zentalis candidates may also be developed in China by Zentera.
Zentalis is also pursuing additional product candidates (WEE1 inhibitor, BCL-2 inhibitor, EGFR inhibitor) targeting distinct cancer pathways that address large patient populations.
Zentalis has raised $20M in a Series A round on May 20, 2020, to establish a Chinese joint Venture, Zentera Therapeutics. Leading the financing is Tybourne Capital Management, a global investment manager headquartered in Asia, and joining the syndicate is OrbiMed Asia, a leading healthcare fund in Asia. Zentalis, through its wholly owned subsidiaries, remains the majority shareholder of Zentera.